Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Dec 2013

Kaplan Henry G

Abstract excerpt

No effective systemic treatment exists for malignant peripheral nerve sheath tumors (MPNSTs). These tumors have been reported to show increased activity in the mitogen-activated protein kinase pathway from the loss of neurofibromatosis-1 regulation and occasionally from BRAF V600E mutation. A patient with sporadic metastatic MPNST and the BRAF V600E mutation was treated with standard doses of sorafenib and later...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Indoles
Share to Nerve Sheath Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Treatment Outcome

Share to Vemurafenib

Source

Identifiers

PMID: 24335681
DOI: 10.6004/jnccn.2013.0173

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.PMID 24335681Read ↗

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma.Semantic proximity Read ↗

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.Semantic proximity Read ↗

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.Semantic proximity Read ↗

Pilomyxoid astrocytoma treated successfully with vemurafenib.Semantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.Semantic proximity Read ↗

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.Semantic proximity Read ↗

Community experience of vemurafenib for BRAF(V600) melanoma.Semantic proximity Read ↗

High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.